NCT05791552 (NL02) is a NA clinical trial of Collection of nasal secretion in Nasal Secretion, sponsored by Noselab GmbH.

Who is sponsoring NCT05791552?

NCT05791552 is sponsored by Noselab GmbH.

What drugs are being tested in NCT05791552?

Interventions in NCT05791552: Collection of nasal secretion.

What condition does NCT05791552 study?

NCT05791552 studies Nasal Secretion, Alzheimer Disease, Brain Nose Interface.

Is NCT05791552 still recruiting?

NCT05791552 is currently status unknown. Last updated 30 March 2023.

Last reviewed 2023-03-30 · How we verify

NCT05791552: NL02

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Feasibility of a Method for Analysis of Alzheimer´s Disease Specific Proteins in Nasal Secretion

Status unknown NA Last updated 30 March 2023

What this trial tests

NA trial testing Collection of nasal secretion in Nasal Secretion in 500 participants. Status unknown.

Timeline

15 February 2022

Primary endpoint
1 June 2023

1 September 2023

Quick facts

Lead sponsor	Noselab GmbH
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	diagnostic
Enrollment	500
Start date	15 February 2022
Primary completion	1 June 2023
Estimated completion	1 September 2023
Sites	1 location across Germany

Drugs / interventions tested

Collection of nasal secretion

Conditions studied

Nasal Secretion — all drugs for Nasal Secretion →
Alzheimer Disease — all drugs for Alzheimer Disease →
Brain Nose Interface — all drugs for Brain Nose Interface →

Sponsor

Noselab GmbH

Who can join

18 and older, any sex, with Nasal Secretion or Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a first in man study investigating the feasibility of the collection, storage, processing and analysis of 4 key biomarkers for the diagnosis of Alzheimer's disease \[AD\] in nasal secretion. Nasal secretion \[NS\] constitutes a minimally invasive access to cerebrospinal fluid \[CSF\]. Therefore, it could be highly suitable for detection and monitoring of the AD relevant biomarkers pTau181, total Tau, Amyloid-ß1-40 and Amyloid-ß1-42. This study evaluates correlations of biomarker patterns in NS and CSF. Furthermore, the correlations of the 4 AD specific biomarkers in nasal secretion and CSF is investigated. For this study, patients with cognitive impairment (AD and NonAD group) and healthy controls were included.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05791552 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Noselab GmbH
Last refreshed: 30 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05791552.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing